{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-168975","form_type":"8-K","ticker":null,"cik":"0001597553","company_name":"Sage Therapeutics, Inc.","filed_at":"2023-06-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.592239+00:00","generated_at":"2026-06-13T22:44:08.499432+00:00","sec_items":["5.02","5.03","5.07","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"Sage Therapeutics stockholders approve ESPP share increase and bylaw amendments at annual meeting","bullets":["Stockholders approved 500,000-share increase to the 2014 ESPP, effective immediately.","Bylaws amended to add universal proxy rules, emergency provisions, and technical updates.","Directors elected: Michael F. Cola, Barry E. Greene, Jeffrey M. Jonas, M.D., Jessica J. Federer as Class III.","Ratified PricewaterhouseCoopers LLP as independent auditor for fiscal year ending Dec 31, 2023.","Advisory vote on executive compensation passed with 39,995,146 for (77.5%) vs 11,173,607 against."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-168975","json":"https://secwatch.observer/filing/0001193125-23-168975.json","markdown":"https://secwatch.observer/filing/0001193125-23-168975.md","text":"https://secwatch.observer/filing/0001193125-23-168975.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1597553/000119312523168975/0001193125-23-168975-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1597553/000119312523168975/d522465d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T22:44:08.499432+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"76d8e3b6d1283acefc82ce2dac1a26d45a525f3b","claim":"Sage Therapeutics, Inc.: Amended and restated bylaws to eliminate requirement for stockholder list at meetings, address technical failures in remote meetings, add emergency bylaws, and revise director nomination procedures under universal proxy rules (effective 2023-06-15).","evidence_excerpt":"On June 15, 2023, the Board approved an amendment and restatement of the Company’s Amended and Restated Bylaws, as amended (as so amended and restated, the “Amended and Restated Bylaws”), effective immediately.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1597553/000119312523168975/0001193125-23-168975-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"bylaw amendment"},{"label":"Effective","value":"2023-06-15"}],"fact_type":"governance_change"},{"claim_id":"20dc998c720ee5b6d2304cd0e2cde62d2e0968c7","claim":"Sage Therapeutics, Inc. shareholders approved Non-binding advisory vote to approve named executive officer compensation.","evidence_excerpt":"A non-binding, advisory proposal on the compensation of the Company’s named executive officers was approved.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1597553/000119312523168975/0001193125-23-168975-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"}],"fact_type":"shareholder_vote"},{"claim_id":"925b45c881a57b2b599e7e57ba27a84bd6e4bf20","claim":"Sage Therapeutics, Inc. shareholders approved Ratify appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm at the 2023-12-31 meeting.","evidence_excerpt":"The appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2023, was ratified.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1597553/000119312523168975/0001193125-23-168975-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-12-31"}],"fact_type":"shareholder_vote"},{"claim_id":"a2cc0b7ece18755ab5ea7e79ab3d0becfd1c726d","claim":"Sage Therapeutics, Inc. shareholders approved Amendment to 2014 ESPP to increase authorized shares by 500,000.","evidence_excerpt":"The amendment to the 2014 ESPP to increase the number of shares of the Company’s common stock authorized for issuance thereunder by 500,000 shares was approved.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1597553/000119312523168975/0001193125-23-168975-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"equity plan"},{"label":"Outcome","value":"passed"}],"fact_type":"shareholder_vote"},{"claim_id":"b8ed5c100cf40e8edb1e670b9da6218c0e8f528a","claim":"Sage Therapeutics, Inc. shareholders approved Election of four Class III directors.","evidence_excerpt":"The following nominees were elected to the Company’s Board as Class III directors for terms expiring at the 2026 annual meeting of stockholders.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1597553/000119312523168975/0001193125-23-168975-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}